Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharming Group NV (PHAR)
The Pharming Group share price today is 1.002, view AS PHAR stock exchange data. Track the latest Pharming Group share price with real-time updates on PHAR stock performance including market cap, day range, 52-week range and dividend yield. Access PHAR charts, earnings dates and analyst estimates to support your investment decisions.
Amsterdam
Currency in EUR
1.002
+0.008(+0.83%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.991
1.009
52 wk Range
0.834
1.818
PHAR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9911.009
52 wk Range
0.8341.818
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHAR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
2.266
Upside
+126.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Form 6K Pharming Group NV For: 4 June- Investing.com
- Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 2.266
(+126.16% Upside)
Pharming Group NV Earnings Call Summary for Q2/2026
- Q2 revenue of $90.2M missed estimates by 10.94%; shares plunged 22% to $0.855, near 52-week low of $0.834 amid investor concerns.
- RUCONEST sales fell 10% YoY to $72.3M due to competition; JOENJA grew 40% YoY to $17.9M but couldn't offset legacy product decline.
- Full-year 2026 revenue guidance cut $30M to $375M-$395M range, implying 0-5% growth; operating expenses reduced $15M to $315M-$320M.
- Management expects RUCONEST stabilization in H2 2026, JOENJA growth continuing at high-30% rate, with Japan launch set for August 2026.
- CEO highlighted pipeline potential with two Phase II studies in immunodeficiencies reporting Q4; CVID opportunity could expand JOENJA to $1B+ blockbuster.
Last Updated: 30-07-2026, 06:06 pm
Read Full TranscriptEarnings
Latest Release
30-07-2026
EPS / Forecast
-- / 0.06
Revenue / Forecast
90.2M / 101.28M
Compare PHAR to Peers and Sector
Metrics to compare | PHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHARPeersSector | |
|---|---|---|---|---|
P/E Ratio | 87.7x | −2.3x | −0.4x | |
PEG Ratio | 0.45 | 0.09 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | 2.2x | 3.0x | 3.1x | |
Upside (Analyst Target) | 141.8% | 125.5% | 47.9% | |
Fair Value Upside | Unlock | 8.8% | 6.3% | Unlock |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Pharming Group (PHAR) Share Price Today?
The Pharming Group share price today is 1.002.
What is the current Pharming Group (PHAR) share price and day range?
As of 17-08-2026, the Pharming Group share price is 1.002, with a previous close of 0.994. The share price has ranged from 0.991 to 1.009 today, while the 52-week range spans from 0.834 to 1.818.
What Is the Pharming Group Market Cap?
As of today, Pharming Group market cap is 708.490M.
What Is the Pharming Group (PHAR) Share Price Target?
The average 12-month share price target for Pharming Group is 2.266, with a high estimate of 2.44772234 and a low estimate of 1.97483731. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +126.16% Upside potential.
What Is Pharming Group's Earnings Per Share (TTM)?
The Pharming Group EPS (TTM) is 0.013.
When Is the Next Pharming Group Earnings Date?
Pharming Group will release its next earnings report on 30-07-2026.
From a Technical Analysis Perspective, Is PHAR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Pharming Group Trade On?
Pharming Group is listed and trades on the Amsterdam Stock Exchange.
What Is the Stock Symbol for Pharming Group?
The stock symbol for Pharming Group is "PHAR."
How Many Times Has Pharming Group Stock Split?
Pharming Group has split 2 times.
How Many Employees Does Pharming Group Have?
Pharming Group has 407 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.